Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1603 in Advanced Solid Tumors or Lymphoma
NCT03722186Phase 1Suspended
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adevilimab in solid tumor (advanced stage) and lymphoma, sponsored by Hengrui. Primary endpoints: Adverse events of SHR-1603 at 18 months, Dose-limited toxicity of SHR-1603 at 18 months and 1 more. Started Nov 2018; status: suspended.
02
Drugs
adevilimab
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03722186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722186.